Phoenix PharmaLabs is very pleased to announce that our chief neuropharmacologist and co-founder, Dr. Lawrence Toll, will present a poster entitled: “In Vitro and In Vivo Profile of PPL-103: A Mixed Opioid Partial Agonist Analgesic or Drug Abuse Medication”, at the upcoming National Center for Advancing Translational Sciences (NCATS)-sponsored symposium The Opioid Crisis and the Future of Addiction [...]
About PPLadminThis author has not yet filled in any details.
So far PPLadmin has created 11 blog entries.
In Pharma Lilly joins the push for non-opioid painkillers 03-Jun-2019 By Maggie Lynch Eli Lilly acquires exclusive worldwide rights for non-opioid treatment for chronic pain from Centrexion through a licensing agreement. HTTPS://WWW.IN-PHARMATECHNOLOGIST.COM/ARTICLE/2019/06/03/ELI-LILLY-LICENSES-NON-OPIOID-TREATMENT-FOR-47.5M
Phoenix PharmaLabs Celebrates Successful Netcapital Equity Offering for Non-Addictive Opioid Pain TreatmentPPLadmin2019-08-02T18:27:42+00:00
Crowdfund Insider Global Banking & Finance Review Biospace
A non-addictive opioid under development by Phoenix PharmaLabs (Utah), PPL-103, has demonstrated the potential to be a treatment for opioid, as well as cocaine, addictions, as published in a poster by Lawrence Toll, PhD, professor of biomedical science at the Charles E. Schmidt College of Medicine at Florida Atlantic University, and chief neuropharmacologist of Phoenix [...]
In Vitro and In Vivo Profile of PPL-101 and PPL-103: Mixed Opioid Partial Agonist Analgesics with Low Abuse PotentialPPLadmin2019-08-02T18:29:03+00:00
Phoenix PharmaLabs has received a Technology Transfer Grant from the National Institutes of Health to evaluate its lead compound as a potential treatment for cocaine addiction. Dr. Larry Toll, our CTO, was recruited earlier this year by Florida Atlantic University to become the University's first recruit under the 21st Century World Class Scholars Program established [...]